Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments.

Merz F, Gaunitz F, Dehghani F, Renner C, Meixensberger J, Gutenberg A, Giese A, Schopow K, Hellwig C, Schäfer M, Bauer M, Stöcker H, Taucher-Scholz G, Durante M, Bechmann I.

Neuro Oncol. 2013 Jun;15(6):670-81. doi: 10.1093/neuonc/not003. Epub 2013 Apr 10. Erratum in: Neuro Oncol. 2014 Sep;16(9):1297.

2.

Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.

Taspinar M, Ilgaz S, Ozdemir M, Ozkan T, Oztuna D, Canpinar H, Rey JA, Sunguroğlu A, Castresana JS, Ugur HC.

Tumour Biol. 2013 Jun;34(3):1935-47. doi: 10.1007/s13277-013-0738-7. Epub 2013 Mar 22.

PMID:
23519841
3.

Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.

Kohsaka S, Takahashi K, Wang L, Tanino M, Kimura T, Nishihara H, Tanaka S.

Cancer Lett. 2013 Apr 30;331(1):68-75. doi: 10.1016/j.canlet.2012.12.005. Epub 2012 Dec 12.

PMID:
23246370
4.

MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.

Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK.

Pediatr Blood Cancer. 2007 Apr;48(4):403-7.

PMID:
16609952
5.

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.

Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M.

J Clin Oncol. 2008 May 1;26(13):2192-7. doi: 10.1200/JCO.2007.14.8163.

PMID:
18445844
6.

Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression.

Bobola MS, Kolstoe DD, Blank A, Silber JR.

Mol Cancer Ther. 2010 May;9(5):1208-18. doi: 10.1158/1535-7163.MCT-10-0010.

7.

N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death.

Zhang J, Hummersone M, Matthews CS, Stevens MF, Bradshaw TD.

Oncology. 2015;88(1):28-48. doi: 10.1159/000366131. Epub 2014 Sep 26.

PMID:
25277441
8.

Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.

Kitange GJ, Mladek AC, Carlson BL, Schroeder MA, Pokorny JL, Cen L, Decker PA, Wu W, Lomberk GA, Gupta SK, Urrutia RA, Sarkaria JN.

Clin Cancer Res. 2012 Aug 1;18(15):4070-9. doi: 10.1158/1078-0432.CCR-12-0560. Epub 2012 Jun 6.

9.

Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.

Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY.

Neuro Oncol. 2013 Jul;15(7):930-5. doi: 10.1093/neuonc/not040. Epub 2013 Apr 3.

10.

Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.

Cen L, Carlson BL, Pokorny JL, Mladek AC, Grogan PT, Schroeder MA, Decker PA, Anderson SK, Giannini C, Wu W, Ballman KV, Kitange GJ, Sarkaria JN.

Neuro Oncol. 2013 Jun;15(6):735-46. doi: 10.1093/neuonc/not010. Epub 2013 Mar 10.

11.

Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.

Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, Wu W, James CD, Sarkaria JN.

Neuro Oncol. 2009 Jun;11(3):281-91. doi: 10.1215/15228517-2008-090. Epub 2008 Oct 24.

12.

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.

van Nifterik KA, van den Berg J, van der Meide WF, Ameziane N, Wedekind LE, Steenbergen RD, Leenstra S, Lafleur MV, Slotman BJ, Stalpers LJ, Sminia P.

Br J Cancer. 2010 Jun 29;103(1):29-35. doi: 10.1038/sj.bjc.6605712. Epub 2010 Jun 1.

13.

Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.

Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S.

Clin Cancer Res. 2014 Nov 15;20(22):5756-67. doi: 10.1158/1078-0432.CCR-13-3389. Epub 2014 Oct 14.

14.

Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?

Hegi ME, Stupp R.

Neuro Oncol. 2015 Nov;17(11):1425-7. doi: 10.1093/neuonc/nov198. Epub 2015 Sep 15. No abstract available.

15.

Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.

St-Coeur PD, Poitras JJ, Cuperlovic-Culf M, Touaibia M, Morin P Jr.

J Neurooncol. 2015 Oct;125(1):91-102. doi: 10.1007/s11060-015-1899-6. Epub 2015 Aug 28.

PMID:
26311249
16.

In vitro evaluation of combined temozolomide and radiotherapy using X  rays and high-linear energy transfer radiation for glioblastoma.

Barazzuol L, Jena R, Burnet NG, Jeynes JC, Merchant MJ, Kirkby KJ, Kirkby NF.

Radiat Res. 2012 May;177(5):651-62. Epub 2012 Apr 2.

PMID:
22468703
17.

MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.

Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W; DIRECTOR Study Group.

Clin Cancer Res. 2015 May 1;21(9):2057-64. doi: 10.1158/1078-0432.CCR-14-2737. Epub 2015 Feb 5.

18.

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.

Melguizo C, Prados J, González B, Ortiz R, Concha A, Alvarez PJ, Madeddu R, Perazzoli G, Oliver JA, López R, Rodríguez-Serrano F, Aránega A.

J Transl Med. 2012 Dec 17;10:250. doi: 10.1186/1479-5876-10-250.

19.

Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.

Happold C, Roth P, Wick W, Schmidt N, Florea AM, Silginer M, Reifenberger G, Weller M.

J Neurochem. 2012 Jul;122(2):444-55. doi: 10.1111/j.1471-4159.2012.07781.x. Epub 2012 May 28.

20.

The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.

Hosein AN, Lim YC, Day B, Stringer B, Rose S, Head R, Cosgrove L, Sminia P, Fay M, Martin JH.

J Neurooncol. 2015 Apr;122(2):263-71. doi: 10.1007/s11060-014-1713-x. Epub 2015 Feb 4.

PMID:
25648357

Supplemental Content

Support Center